What ACADIA Pharmaceuticals (ACAD) Said on Its Q3 Earnings Call
ACADIA Pharmaceuticals (ACAD) reported Q3 earnings, highlighting a U.S. patent extension for DAYBUE until 2041. NUPLAZID sales grew 12% to $202M, with full-year guidance narrowed to $760M-$775M. The company expects $1.265B-$1.295B in 2026 revenue. R&D expenses fell to $76M, while SG&A rose to $159M. ACADIA remains confident in a NUPLAZID patent appeal and plans to refine its remlifanserin trial for Alzheimer's disease psychosis.
How this was made
The 30-second read
Why it matters
The earnings beat on R&D spend but miss on trial data creates a mixed outlook; investors will weigh guidance cuts against pipeline potential.
Market read
The earnings release provides fresh guidance and trial data that directly affect Acadia's valuation and may influence the broader CNS biotech sector.
What to watch
Potential European patent protection for DAYBUE could extend market exclusivity and improve long‑term margins.
Background
Acadia Pharmaceuticals reported Q3 results, updated guidance, and provided updates on its pipeline, including a missed primary endpoint in a Phase II study.
Ticker impact
Q3 earnings call disclosed narrowed full-year NUPLAZID sales guidance to $760‑$775M and FY2026 revenue to $1.265‑$1.295B, plus a Phase II trial miss for remlifanserin.
likely pressure as the market prices in lower sales guidance and trial disappointment
Revenue and sales guidance are materially lower than prior expectations; trial miss reduces near‑term pipeline confidence.
Market effects
Neuro‑psychiatric drug sector may see modest repricing as peers' pipelines are re‑evaluated.
U.S. biotech index could face slight downside pressure.
Limited to investors focused on CNS therapeutics and specialty pharma.
Counterpoint
If the expanded sales force drives volume growth faster than expected, the guidance cut may be overly conservative.
Key entities
- companyAcadia Pharmaceuticals
Biopharma focused on CNS and neuropsychiatric disorders.
- productNUPLAZID
Acadia's marketed antipsychotic for Parkinson's disease psychosis.
